38-1A2 is a specific antibody that binds precisely to two tandem VHH sequences of LCAR-B38M. These sequences are designed to target two epitopes of the B-cell maturation antigen (BCMA). BCMA is a protein expressed selectively by B-lineage cells, including both normal and malignant plasma cells in multiple myeloma. Ciltacabtagene autoleucel, also known as cilta-cel or Carvykti, is a gene-edited autologous CAR T-cell therapy. It utilizes LCAR and B38M to effectively recognize BCMA-positive cells.

Flow cytometric analysis of anti-LCAR-B38M CAR expression on human cell line Jurkat cells. Jurkat cells were transduced with lentivirus encoding LCAR-B38M CAR and cultured. 2×105 cells were stained for the expression of Rabbit Anti-LCAR-B38M Monoclonal Antibody, Alexa Fluor 647 (Product No.212701, right panel). Non-transduced Jurkat cells were used as a control for gating of CAR expression (left panel).
| Product No. | 212701 |
| Size | 25 tests |
| Recommended Vol. per Test | 1 μL |
| Antibody Types | Monoclonal |
| Antibody Format | Whole IgG |
| Clone | 38-1A2 |
| Immunogen | Two tandem VHH sequences of LCAR-B38M |
| Conjugate | Alexa Fluor 647 |
| Excitation/Emission Max | 651/667nm |
| Host Species | Rabbit |
| Storage Buffer | Aqueous buffered solution containing protein stabilizer and ≤0.05% ProClin 300 |
| Storage conditions | 2-8°C, store in dark |
©2026 Cytoart. All Rights Reserved.